Fundraising Fox
TScan Therapeutics
Boston, US · Founded 2018 · 152 employees on LinkedIn · 7 known investors
Find your way into TScan Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
116 people can intro you to David
Ask Nilay Thakar to introduce you to David P. Southwell
You →Nilay · together at Volastra →David
Sign up to find every way you can get introduced to TScan Therapeutics
- Your email: who you already know at TScan Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the TScan Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
A company focused on developing clinical treatments aimed at improving patient outcomes.
Founders & leadership
DS
David SouthwellPresident and Chief Executive Officer2018–2023David Southwell has held roles spanning healthcare operations, finance, mergers and acquisitions, product launches, and board governance across healthcare, private equity, and investment banking.
RC
Robert CraneExecutive
Board
LH
SK
CM
HS
CW
TB
Timothy BarberichBoard director
Investors · 7
Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M
How we know: Astellas Venture Management LLC's portfolio page · Not right? Tell us
Bessemer Venture Partnerslisted by Bessemer Venture PartnersSan Francisco · $5M – $100M
How we know: Bessemer Venture Partners's portfolio page · Not right? Tell us
GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M
How we know: GV (Google Ventures)'s portfolio page · Not right? Tell us
Longwood Fundlisted by Longwood FundBoston
How we know: Longwood Fund's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$123.3M disclosed across 2 rounds · 2019–2021
▶$100MraisedJan 2021 · 16 investors · BiotechnologyRule 506(b)
▶$100MraisedJan 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ittai HarelDirector
- Nandita ShangariDirector
- Christoph WestphalDirector
- Brian SilverDirector
- Doug FambroughDirector
- Timothy BarberichDirector
- David SouthwellExecutive Officer, Director
- Andrew HedinDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$23.3MraisedJul 2019 · 9 investors · BiotechnologyRule 506(b)
▶$23.3MraisedJul 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lea HachigianDirector
- David SouthwellExecutive Officer, Director
- Steve KrausDirector
- Campbell MurrayDirector
- Hannes SmarasonDirector
- Christoph WestphalDirector
- Robert CraneExecutive Officer
- Timothy BarberichDirector
- Offering amount
- $23.3M
- Amount sold
- $23.3M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies working in the same space as TScan Therapeutics.
Frequently asked questions
- What does TScan Therapeutics do?
- A company focused on developing clinical treatments aimed at improving patient outcomes.
- Who are TScan Therapeutics's investors?
- TScan Therapeutics's investors include Astellas Venture Management LLC, Bessemer Venture Partners, GV (Google Ventures), Longwood Fund, RA Capital, 6 Dimensions Capital, Pitango.
- How much funding has TScan Therapeutics raised?
- TScan Therapeutics has disclosed $123.3M raised across 2 rounds.
- Where is TScan Therapeutics headquartered?
- TScan Therapeutics is headquartered in Boston, US.